Arbutus Biopharma (ABUS) Tops Q3 EPS by 20c

Arbutus Biopharma (NASDAQ: ABUS) reported Q3 EPS of ($0.17), $0.20 better than the analyst estimate of ($0.37).

For earnings history and earnings-related data on Arbutus Biopharma (ABUS) click here.

You May Also Be Interested In

• onsemi downgraded by TD Cowen after Synaptics deal clouds growth story
• Morgan Stanley Assumes Prada SpA (1913:HK) (PRDSY) at Equalweight
• Aristocrat Leisure (ALL:AU) (ARLUF) PT Raised to AUD66 at RBC Capital